Abivax SA Sponsored ADR (ABVX) Stock Forecast & Price Target

Compare

167 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ABVX Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Abivax

SA Sponsored ADR

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ABVX Stock 12 Month Forecast

Average Price Target

$79.29

▲(692.90%Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Abivax SA Sponsored ADR in the last 3 months. The average price target is $79.29 with a high forecast of $101.00 and a low forecast of $43.00. The average price target represents a 692.90% change from the last price of $10.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","53":"$53","102":"$102","28.5":"$28.5","77.5":"$77.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":101,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$101.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":79.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$79.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$43.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,28.5,53,77.5,102],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.66,14.84,22.020000000000003,29.200000000000003,36.38,43.56,50.74000000000001,57.92,65.10000000000001,72.28,79.46000000000001,86.64,93.82000000000001,{"y":101,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.66,13.170000000000002,18.68,24.19,29.700000000000003,35.21000000000001,40.72,46.230000000000004,51.74000000000001,57.25,62.760000000000005,68.27000000000001,73.78,{"y":79.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.66,10.37846153846154,13.096923076923078,15.815384615384616,18.533846153846156,21.252307692307696,23.970769230769232,26.68923076923077,29.40769230769231,32.126153846153855,34.844615384615395,37.56307692307693,40.28153846153846,{"y":43,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.97,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.04,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.56,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.71,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.97,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.48,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.32,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.68,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.89,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.91,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.35,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.66,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$101.00

Average Price Target$79.29

Lowest Price Target$43.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$68

Hold

580.00%

Upside

Reiterated

07/24/25

Abivax SA's overall stock score is primarily impacted by its poor financial performance, characterized by operational losses and high leverage. While technical analysis shows bullish momentum, the valuation remains unattractive due to negative earnings. Without additional positive catalysts or improvements in profitability, the stock faces significant risks.

Judah FrommerMorgan Stanley

Morgan Stanley

$12→$71

Buy

610.00%

Upside

Upgraded

07/24/25

Abivax upgraded to Overweight from Equal Weight at Morgan StanleyAbivax upgraded to Overweight from Equal Weight at Morgan Stanley

Thomas SmithLeerink Partners

Leerink Partners

$20→$74

Buy

640.00%

Upside

Reiterated

07/23/25

Abivax SA's Obefazimod: Strong Phase 3 Results and Promising Market Potential Justify Buy Rating

Allison BratzelPiper Sandler

Piper Sandler

$42→$70

Buy

600.00%

Upside

Reiterated

07/23/25

Abivax price target raised to $70 from $42 at Piper SandlerAbivax price target raised to $70 from $42 at Piper Sandler

Sam SlutskyLifeSci Capital

LifeSci Capital

$45→$101

Buy

910.00%

Upside

Reiterated

07/23/25

Analysts Offer Insights on Healthcare Companies: Krystal Biotech (NASDAQ: KRYS), Abivax SA Sponsored ADR (NASDAQ: ABVX) and Kyowa Kirin Co (Other OTC: KYKOF)

Yatin SunejaGuggenheim

Guggenheim

$50→$101

Buy

910.00%

Upside

Reiterated

07/23/25

Abivax price target raised to $101 from $50 at GuggenheimAbivax price target raised to $101 from $50 at Guggenheim

Jason ButlerCitizens JMP

Citizens JMP

$33→$95

Buy

850.00%

Upside

Reiterated

07/23/25

Abivax price target raised to $95 from $33 at Citizens JMPAbivax price target raised to $95 from $33 at Citizens JMP

Julian HarrisonBTIG

BTIG

$43

Buy

330.00%

Upside

Reiterated

07/22/25

Promising Phase 3 Results and Broad Market Potential Drive Buy Rating for Obefazimod

Yale JenLaidlaw

Laidlaw

$48

Buy

380.00%

Upside

Initiated

07/29/24

Abivax initiated with a Buy at LaidlawAbivax initiated with a Buy at Laidlaw

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$68

Hold

580.00%

Upside

Reiterated

07/24/25

Judah FrommerMorgan Stanley

Morgan Stanley

$12→$71

Buy

610.00%

Upside

Upgraded

07/24/25

Abivax upgraded to Overweight from Equal Weight at Morgan StanleyAbivax upgraded to Overweight from Equal Weight at Morgan Stanley

Thomas SmithLeerink Partners

Leerink Partners

$20→$74

Buy

640.00%

Upside

Reiterated

07/23/25

Abivax SA's Obefazimod: Strong Phase 3 Results and Promising Market Potential Justify Buy Rating

Allison BratzelPiper Sandler

Piper Sandler

$42→$70

Buy

600.00%

Upside

Reiterated

07/23/25

Abivax price target raised to $70 from $42 at Piper SandlerAbivax price target raised to $70 from $42 at Piper Sandler

Sam SlutskyLifeSci Capital

LifeSci Capital

$45→$101

Buy

910.00%

Upside

Reiterated

07/23/25

Analysts Offer Insights on Healthcare Companies: Krystal Biotech (NASDAQ: KRYS), Abivax SA Sponsored ADR (NASDAQ: ABVX) and Kyowa Kirin Co (Other OTC: KYKOF)

Yatin SunejaGuggenheim

Guggenheim

$50→$101

Buy

910.00%

Upside

Reiterated

07/23/25

Abivax price target raised to $101 from $50 at GuggenheimAbivax price target raised to $101 from $50 at Guggenheim

Jason ButlerCitizens JMP

Citizens JMP

$33→$95

Buy

850.00%

Upside

Reiterated

07/23/25

Abivax price target raised to $95 from $33 at Citizens JMPAbivax price target raised to $95 from $33 at Citizens JMP

Julian HarrisonBTIG

BTIG

$43

Buy

330.00%

Upside

Reiterated

07/22/25

Promising Phase 3 Results and Broad Market Potential Drive Buy Rating for Obefazimod

Yale JenLaidlaw

Laidlaw

$48

Buy

380.00%

Upside

Initiated

07/29/24

Abivax initiated with a Buy at LaidlawAbivax initiated with a Buy at Laidlaw

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Abivax SA Sponsored ADR

1 Month

xxx

Success Rate

4/11 ratings generated profit

Average Return

+67.92%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 36.36% of your transactions generating a profit, with an average return of +67.92% per trade.

3 Months

xxx

Success Rate

5/11 ratings generated profit

Average Return

+205.41%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 45.45% of your transactions generating a profit, with an average return of +205.41% per trade.

1 Year

Julian HarrisonBTIG

Success Rate

5/7 ratings generated profit

Average Return

+486.46%

reiterated a buy rating 4 days ago

Copying Julian Harrison's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +486.46% per trade.

2 Years

xxx

Success Rate

11/11 ratings generated profit

Average Return

+621.88%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +621.88% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABVX Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ABVX has received 14 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. ABVX average Analyst price target in the past 3 months is 79.29.

Each month's total comprises the sum of three months' worth of ratings.

ABVX Financial Forecast

ABVX Earnings Forecast

Next quarter’s earnings estimate for ABVX is -$0.93 with a range of -$0.95 to -$0.91. The previous quarter’s EPS was -$0.97. ABVX beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 39.53% of the time in the same period. In the last calendar year ABVX has Outperformed its overall industry.

No data currently available

ABVX Sales Forecast

Next quarter’s sales forecast for ABVX is $1.40M with a range of $1.36M to $1.43M. The previous quarter’s sales results were ―. ABVX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 53.97% of the time in the same period. In the last calendar year ABVX has Preformed in-line its overall industry.

ABVX Stock Forecast FAQ

What is ABVX’s average 12-month price target, according to analysts?

Based on analyst ratings, Abivax SA Sponsored ADR’s 12-month average price target is 79.29.

What is ABVX’s upside potential, based on the analysts’ average price target?

Abivax SA Sponsored ADR has 692.90% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ABVX a Buy, Sell or Hold?

Abivax SA Sponsored ADR has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Abivax SA Sponsored ADR’s price target?

The average price target for Abivax SA Sponsored ADR is 79.29. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $101.00 ,the lowest forecast is $43.00. The average price target represents 692.90% Increase from the current price of $10.

What do analysts say about Abivax SA Sponsored ADR?

Abivax SA Sponsored ADR’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of ABVX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Abivax SA Sponsored ADR (ABVX) Stock Forecast & Price Target

ABVX Analyst Ratings

ABVX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Abivax SA Sponsored ADR

ABVX Analyst Recommendation Trends

ABVX Financial Forecast

ABVX Earnings Forecast

ABVX Sales Forecast

ABVX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts